Sickle cell disease is an autosomal recessive condition that results from the presence of a mutated form of hemoglobin. Some genetic variants of BCL11A are amenable to therapeutic manipulation. The present study investigated the relationship of a BCL11A variant (rs1427407) and its plasma levels with vaso-occlusive crises and stroke complications among patients in Sudan with sickle cell disease. Methods: This cross-sectional study was performed between June 2014 and October 2016. The subjects included 166 patients who were diagnosed with sickle cell disease and 35 healthy control subjects, who were grouped according to sex and age (<15 years, 15-25 years, and >25 years). All patients and/or their guardians provided informed consent. Blood samples were collected from the patients and controls under aseptic conditions. Results: Plasma BCL11A levels were elevated in cases with vaso-occlusive crises that lasted for >3 years. In addition, plasma BCL11A levels were high in cases with the GG genotype (vs. GT and TT) at rs1427407. Furthermore, the BCL11A rs1427407 GG/GT genotypes increased the risk of vaso-occlusive crisis and stroke in the patients with sickle cell disease. Conclusion: The BCL11A variant (rs1427407) and its plasma levels were associated with vaso-occlusive crisis and stroke in patients with sickle cell disease.
INTRODUCTION
Sickle cell disease (SCD) is an autosomal recessive condition that results from the presence of a mutated form of hemoglobin. It is the most common inherited blood disorder in the United Kingdom, where it affects 12,000-15,000 people among approximately 250,000 carriers of the sickle cell gene. 1) Globally, SCD is most common among people of West African or Caribbean descent.
2) The cause of SCD is a single nucleotide substitution in the beta globin gene on the short arm of chromosome 11. The resulting protein, hemoglobin S, polymerizes under low oxygen conditions, causing red blood cells to become rigid and sickle-shaped. These sickle cells cause the activation of other circulating cells, including neutrophils, and blood vessel walls as part of processes similar to those observed in vasculopathies. The tissue subsequently loses its blood supply, and the resulting ischemia causes tissue infarction.
3) The most common manifestations are painful vaso- healthy subjects were recruited to create a control group with similar age and sex characteristics. The subjects and/or their guardians provided informed consent to participate in the study after receiving a detailed explanation regarding the purpose of the study and any related risks. Blood samples were collected from the patients and controls under aseptic conditions using an ethylenediaminetetraacetic acid-coated vacutainer tube. 
RESULTS
The characteristics and laboratory test results for the SCD patients and controls are shown in Table 1 . There were no significant differences between the two groups according to age (P=0.9239) or sex (P=0.4316).
In addition, no significant differences were observed between the 116 SCD patients and the 35 controls according to mean red blood cell count (P=0.3916), mean corpuscular volume (P=0.9426), or mean corpuscular hemoglobin level (P=0.5288). However, there were significant differences in the mean white blood cell count (P=0.0001), platelet count (P=0.0001), HbF percentage (P=0.0001), reticulocyte count (P=0.0001), and plasma BCL11A level (P=0.0001).
The rs1427407 sequencing revealed three genotypes: GG, GT, and TT. The distributions of the genotypes among the SCD patients and healthy controls are shown in Table 2 . Our results have been verified by the fact that SCD is associated with the BCL11A genotype polymorphism. The BCL11A genotypes that included the T allele and the G allele at rs1427407 were common among SCD patients. We evaluated whether SCD complications were associated with the various genotypes, and found that the BCL11A rs1427407 GG and GT genotypes had significantly elevated risks of SCD complications (P=0.0008) (Table 2).
The plasma BCL11A levels were measured in SCD patients according to their VOC duration (Figure 1 ), which revealed that plasma BCL11A levels were elevated among patients with a VOC duration of >3 years. In addition, plasma BCL11A levels were higher in patients with the GG genotype than in patients with the GT and TT genotypes ( Figure 2 ). The frequencies of the BCL11A rs1427407 genotypes according to SCD complications are shown in Table 3 . We found that the GG, GT, and TT genotypes had significantly different VOC durations (P=0.0004) and significantly different rates of stroke (P=0.008) ( Table   3 ). Thus, the BCL11A rs1427407 GG/GT genotypes appear to be associated with increased risks of VOC and stroke among SCD patients.
DISCUSSION
The BCL11A rs1427407 variant is commonly found in SCD patients.
12)
The BCL11A gene was first detected in B-cell chronic lymphocytic leukemia and is a protooncogene for malignant hematological diseases. 13, 14) Our study revealed that SCD patients had plasma BCL11A levels that were significantly higher than the control subjects (100.13 µg/L versus 70.88 µg/L, P<0.05). Furthermore, the SCD patients had a higher frequency of the GG and GT genotypes at BCL11A rs1427407. Moreover, the BCL11A rs1427407 GG variant increased the risk of developing SCD (Table 2) . Some studies have also indicated that BCL11A can be used to predict overall and disease-free survivals. 15, 16) In our study, the plasma BCL11A levels increased according to the duration of VOC in SCA patients. However, previous studies have revealed conflicting data regarding the associations between BCL11A variants and SCA-related complications, such as VOC frequency 11, 17) and stroke. 11, 18) We observed statistically significant problems with the inheritance of BCL11A rs1427407 in >3 VOC/y or stroke, while the frequency of BCL11A rs1427407 genotypes was significantly related to vaso occlusive (VOc) periods in SCA patients (Table 3) . Therefore, plasma BCL11A levels appear to be higher for more advanced VOC relative to the more initial stages (Figure 1 ). Our study also revealed that the BCL11A rs1427407 genotypes (GG/GT/TT) were significantly associated with stroke complications among SCD patients, and this finding agrees with the results of Satraf et al. 19) The presence of BCL11A rs1427407 appears to reflect a genetic hazard profile with a higher reticulocyte percentage and higher risk of stroke (Table 3 ). The association with VOC duration of >3 years also indicates that this genetic profile was strongly associated with markers of hemolysis and it appears that the presence of SCA is related to stroke complications. Our findings also agree with a previous report that a decreased hemoglobin level is a risk factor for stroke (Table 1) , 19) and that increased markers of hemolysis are independently associated with increased reticulocytes and silent strokes. 20) Relative to the studies performed by Saraf et al. 19) and Kwiatkowski et al., 21) our study has several useful parameters. For example, regardless of the cross-sectional design, we evaluated variations in stroke history according to the BCL11A rs1427407 genotypes by retrospectively collecting stroke records that were prepared using a medical evaluation tool. This may have reduced the risk of detection bias and protected against including silent infarcts in this analysis, which increased the likelihood of identifying VOC and stroke in SCD patients.
In conclusion, the present study revealed that the BCL11A rs1427407 genotypes and elevated BCL11A plasma levels were associated with the risk of stroke, which indicates that genetic factors influence the degree of hemolysis and HbF levels, which may improve our ability to identify SCA patients who are experiencing these complications. Furthermore, plasma BCL11A levels were elevated in patients with the GG/GT genotype of BCL11A rs1427407. To the best of our knowledge, this is the first study to evaluate the genetic influence on SCA severity among Sudanese patients, which may help improve the medical management of these cases. However, our findings must be validated by larger studies. Nevertheless, if further research confirms our results, our findings may indicate that genetic evaluations can help improve the treatment of patients with SCA who are experiencing stroke complications or VOC. 
